TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > Our Services > Clinical Program Development

Clinical Program Development

Clinical Program Development

Confidence Beyond Compliance

PharmaLex provides global Clinical Development / Clinical Regulatory expertise to support every step of the clinical development pathway, from first in man studies through registration studies as well as post approval programs.

Our aim is to help our clients strategically navigate through the various phases of clinical development to ensure the client creates a robust, innovative strategy to maximize asset value and the probability of success.

Our services include:

Clinical Development and Clinical Strategy Consulting

Our expert clinical development team will partner with our client to create a Target Product Profile (TPP) which will serve as a solid foundation on which to guide clinical development in support of the targeted label indication, and improve communication to regulatory authorities. Our blend of expertise in clinical, regulatory and clinical statistics understand that each of our clients have unique and different clinical development needs. Together this team looks at our clients milestones, end goals and through provision of innovative clinical development knowledge, create a clinical development program designed to gain both regulatory approval and achieve commercial success.

PharmaLex’s clinical development differentiator is our cross-functional and clinically focused team who provide innovative strategic and tactical solutions to optimize and de-risk drug development.

Synopsis and protocol Development

  • Insightful and forward strategic design of individual Protocol / Synopsis for clinical trials that incorporate current best practice and are aligned with regulatory guidance and precedence
  • Includes the opportunity to answer key questions and gaps and explore additional supportive potential benefits or points of differentiation.
  • Innovative clinical trial and program design with strategic endpoint development (including patient-reported outcome measures) supporting differentiated labels, adaptive features in Phase II and III trials, and safety evaluation plans for specific adverse events or interest.

Synopsis and protocol Development

  • Insightful and forward strategic design of individual Protocol / Synopsis for clinical trials that incorporate current best practice and are aligned with regulatory guidance and precedence
  • Includes the opportunity to answer key questions and gaps and explore additional supportive potential benefits or points of differentiation.
  • Innovative clinical trial and program design with strategic endpoint development (including patient-reported outcome measures) supporting differentiated labels, adaptive features in Phase II and III trials, and safety evaluation plans for specific adverse events or interest.

Clinical Statistical Team provide the following services

  • Statistical input to the study design and protocols for sample sizing, randomization and statistical analysis plans
  • Simulation, PK / PD modelling and analysis
  • Benefit Risk Analysis
  • Pediatric development, rare and orphan disease
  • Biomarker and bioassay qualification
  • Analyses of complex data and signals

Clinical Development Medical Writing Services

  • Provision of clear and concise documents
  • Clinical study reports, protocols, CRF Design, investigator’s brochures, manuscripts,
  • Toxicological non-clinical and clinical expert statements

Clinical Program Manager Services

  • Provide strategic overall management of the project and will be the point of contact between the client and PharmaLex
  • Managing the overall clinical development program and monitoring progress and budget
  • Identifying and managing risks and issues and taking corrective actions
  • Coordinating the projects and vendors required for the clinical program and their interdependencies and managing resources across projects

Related News

Addressing Limitations of Sterility Testing
Addressing Limitations of Sterility Testing
9th May 2022
Are virtual audits sustainable post-pandemic?
Are virtual audits sustainable post-pandemic?
6th May 2022
Is quality documentation an asset or a burden in regulatory affairs?
Is quality documentation an asset or a burden in regulatory affairs?
6th April 2022

Related Resources

Thought Leadership

  • Estimate your probability of success with Bayesian statistics
  • ABPI Code feedback
  • The use of LinkedIn and the ABPI Code of Practice
  • Agencies and the ABPI code of practice
  • How does the ABPI Code apply to congresses?
  • Together Beyond COVID-19 - A Look to the Future
  • Why you never really validate your analytical method unless you use the total error approach (part II: Producer and Consumer risks)
  • The Outlook for a Year of Change
  • Why you never really validate your analytical method unless you use the total error approach (part I: concept)
  • New SAS solutions for Population PK Model
  • Bayesian Power, Assurance and Probability of Success: Reproducibility Issues
  • Bayesian Power, Assurance and Probability of success: A quick who’s who
  • Proposal for a Single Arm Clinical Study in Rare Disease using Bayesian Statistics
  • IPI publication: Non-clinical safety evaluation of vaccines accelerating clinical development
  • Chemistry Today publication: Non-clinical safety evaluation of vaccines accelerating clinical development
  • Teknoscience publication: Successful marketing of medicinal cannabis
  • Supporting M&As in the pharmaceutical/biopharmaceutical industry
  • Successful marketing of medicinal cannabis part II
  • Successful marketing of medicinal cannabis part I
  • Non-clinical safety evaluation of vaccines part II
  • Non-clinical safety evaluation of vaccines part I
  • Improving the chances of EU approval
  • IPI publication: Successful marketing of medicinal cannabis
  • Can a robust QMS help you achieve customer satisfaction?
  • Product Launch
  • Together Beyond COVID-19
  • Learning Lessons from Nitrosamine Impurities
  • Quality Investigations & CAPAs "Elementary, my dear Watson"​
  • Drug Development Decisions
  • The FDA is shifting focus to both ends of the NPD spectrum
  • EPR - the regulatory intelligence the platform deserves
  • Latin America Leans Towards Greater Regulatory Harmonization
  • Spot the Difference
  • In the case of a ‘no deal’ Brexit: the supply of medicines
  • The Evolving Influence of the FDA on Pharma
  • Regulatory intelligence – from knowledge to added value
  • TOPRA // Regulatory Rapporteur Vol 15, No 10, October 2018
  • Improving Availability of Medicines in the EU
  • EMA simplifies the process for internal transfer of MAs
  • Brexit Uncertainty - impact on medicines supply
  • AI in drug development|Pharmacovigilance
  • Digitally Transforming Pharma’s Regulatory Processes
  • AI in drug development: Regulatory Affairs - Part 1: Regulatory Affairs
  • Moving From Artificial Trials To Smarter Regulatory Process
  • The 5 things you want to know about Artificial Intelligence

Fact Flyers

  • Strategic Regulatory Operations
  • Signal Management Activities Customization
  • SMARTVIGILIT - Flyer
  • RADIOPHARMA-EXPERTISE @PHARMALEX
  • SMARTVIGICONTRACT - Flyer
  • SMARTRISK - Flyer
  • SMARTVIGISCREEN - Flyer
  • Validation Services
  • Pharmacovigilance Services postcard
  • Commissioning and Qualification (C&Q)
  • FDA meetings and health authority interactions
  • Medical Device Regulations Transition Support
  • Medical Devices for the Pharmaceutical Industry
  • Veeva Vault RIM Implementation
  • PharmaLex Overview of Services
  • ATMP Quick Links and Guidelines
  • Biosimilar Quick Links and Guidelines
  • Health Economics
  • Advanced Therapies - Navigating through the Regulatory Framework
  • Orphan Medicine Development
  • Value Added Medicines
  • GxP - Operate a functional and efficient QMS
  • Regulatory Submissions for Tobacco and Vape Products
  • Regulatory Affairs Application Services
  • Regulatory Compliance - CMC Implementation
  • Biopharmaceuticals CMC
  • Real World Evidence
  • Writing Capabilities
  • Health Authority Interactions
  • Regulatory Compliance
  • Chemistry, Manufacturing and Control (CMC)
  • Portfolio Maintenance Outsourcing
  • Medical Information Services
  • Medical Device Services

Case Studies

  • Business Continuity during Merger
  • Start Up as Wholesale Distributor with business expansion plans
  • Case Processing Services
  • Support with retrieval of ICSR Follow-Up information
  • Global PV Outsourcing
  • Full PV Outsourcing of a Global Generics Pharma Company
  • Safety Detection and Signal Management
  • Drug Product Release Specification Justification
  • Data Science long-term support to a global submission dossier
  • Tolerance intervals solution
  • Setting calibration frequency for an IVD
  • System suitability control limits for assay with format
  • Preparing for process characterization activities
  • Post-regulatory support to an EMA clinical submission
  • Setup an Atlassian product (Jira, confluence)
  • Validation of SoftMaxPro
  • Development and Implementation of the Robustness Index
  • Dilution recipe for vaccine production
  • Implementing parallelism tests in JMP
  • Continuous Manufacturing: Development, Optimization and Validation
  • Biosimilarity assessment on multiple CQAs
  • Bayesian modelling and prediction of patient recruitment
  • Automatic detection of disease events based on accelerometer data
  • Analytical Method Comparisons
  • Acceptance criteria for Bioassay validation
  • PharmaLex successfully changes legal status of product from POM to P
  • PharmaLex keeps medical device CE marking on track
  • PharmaLex expertise secures CE certification for medical devices ‘at risk’
  • PharmaLex delivers huge sales upturn with regulatory strategy
  • PharmaLex corrects serious non-compliance issue
  • PharmaLex creativity achieves increased cosmetic product sales
  • PharmaLex obtains rapid CE marking
  • PharmaLex applies EU regulatory affairs expertise
  • Outsourcing pharmacovigilance activities to PharmaLex
  • Computer Software Validation for Multinational Pharmaceutical Company
  • Outsourcing clinical trial safety activities to PharmaLex
  • Portfolio Maintenance Outsourcing Local RA responsibility – EU
  • Safety Writing Services
  • Aggregate Report Writing and RMPs
  • Remediation Activities and Operational Support
  • Business Readiness for new German Affiliate
  • Pre-IND Meeting for an antibody-drug conjugate (ADC) for an advanced cancer indication
  • Medical Information Service for mid-sized pharma company
  • Medical Information Service for large pharma company
  • Full service Post-Marketing Pharmacovigilance and Medical Information Services for large nutritional health company
  • Parallel NDA/MAA eCTD Submission
  • Regulatory Operations IND transition to eCTD
  • Full service post-marketing and clinical trial PV activities for mid-sized pharma company
  • MA applications to EMA and FDA in parallel
  • Dendritic cell vaccine (oncology)
  • Regulatory CMC Compliance reduced risk
  • Definition of batches internal release limits based on stability results
  • Pre-IND Meeting
  • Type C Meeting
  • End of Phase-2 meeting
  • RIM-DMS Data Clean-up
  • Veeva Vault RIM Implementation
  • Consultancy and eCTD submission support for master files
  • Consultancy and support for IDMP implementation
  • Portfolio Maintenance Outsourcing – Global RA responsibility
  • Strategic outsourcing of mature product portfolio
  • Portfolio maintenance outsourcing in highly volatile environment
  • Global CMC responsibility during portfolio integration
  • End-2-end portfolio maintenance (outsourcing) program
  • Post–M&A PharmaLex program governance
  • Post–M&A pharma infrastructure development
  • M&A early strategy
  • Lifecycle management for drug products
  • Regulatory CMC compliance reduced workload by 20-25%
  • Full PV service outsourcing
  • Flexible eCTD publishing support
  • eCTD submissions for global DMF portfolio
  • Regulatory publishing support on request
  • Local lifecycle Regulatory Affairs management
  • Due diligence for medicinal product documentation
  • Multi-country Phase III clinical trial support
  • US-UK Phase II clinical trial support
  • Preparation, submission and coordination of a CP for PUMA
  • Strategy and delivery of global biosimilar development program
  • ERA for an active substance in antiseptic lozenges

White Papers

  • Transport risk assessment and verification - from theory to practice.
  • Managing mature product portfolios - Key challenges and benefits
  • Pharma's growing interest in probiotics - a challenge or an opportunity?
  • Inspection Readiness Audit - Gap Analysis - Mock Inspections
  • Considerations When Applying for a Generic Medicine Authorisation
  • When your notified body is losing its designation under the medical device regulation
  • Top tips for a successful EU Orphan Drug Designation application
  • Tips for writing an outstanding Clinical Overview
  • The Medical Literature Monitoring of the EMA
  • Monitoring Compliance with Safety Exchange Agreements
  • Implementation of Eudravigilance Data Analysis System (EVDAS) in signal detection
  • QMS aspects of the Medical Device Regulation
  • Legal status switches in the UK
  • Mutual recognition of inspections of medicinal product manufacturers between the EU and the USA
  • The medical device regulations and their implications on device vigilance
  • New responsibilities for importers
  • EU drug registration procedures
  • Preparing for a Good Pharmacovigilance Practice MHRA Inspection
  • Successful marketing of medicinal cannabis and cannabis-derived products - Part II
  • Successful marketing of medicinal cannabis and cannabis-derived products
  • EU Clinical Trial Regulation
  • How will clinical trials be regulated after 1 January 2021?
  • In Vitro Diagnostic Medical Devices Regulation – Summary of changes and impact for manufacturers
  • Medical Device Software and Mobile Apps
  • Navigating the regulatory submission process for a class III medical device with ancillary medicine
  • UK Pharmacovigilance Requirements Following the End of the Brexit Transition Period
  • Non-clinical safety evaluation of vaccine: strategic considerations to accelerate clinical development
  • How will Medical Devices be regulated following the end of the Brexit Transition Period
  • Together Beyond COVID-19 - A Look at the Future
  • The Challenges of Achieving and Maintaining CMC Compliance
  • Analysis of EMA's Product Management Services
  • Together Beyond COVID-19: Key trends that have been accelerated by the pandemic
  • Brexit Considerations for Industry: The current Position
  • Nitrosamines - information for MAHs
  • The Medical Device Regulation – Readiness for May 2021
  • Software, AI and Medical Devices - What's Up?
  • Pre-IND meetings | The opportunity for early FDA feedback
  • Differing CMC requirements: US and EU
  • Five secrets of great publishers
  • Manage effectively your Merger and Acquisition activities

Webinars

  • How technology optimizes the publishing process for regulatory submissions
  • Bayesian Expert Prior Elicitation to Aid Decision Making in Biopharmaceutical Development
  • Software Medical Devices – Considerations for Regulatory Compliance Success
  • How technology optimizes the publishing process for regulatory submissions
  • Bench to Bedside: The need for an Integrated Product Strategy
  • Manufacturing and regulatory challenges in Cell, Gene and Tissue Therapies/ATMPs
  • Bayesian Statistics: Model to predict recruitment and inform supply chain
  • Global framework of interactions with Heath Care Professionals : Loi anti-cadeaux in France
  • Using R Shiny for Bayesian Prior Determination and Clinical Trial Design
  • Gene therapy products: regulatory expectations and challenges for the industry
  • Bayesian Methods for Joint Longitudinal and Survival Data
  • Remediation and Preparations: a recap of current state and what is next for Medical Devices and In Vitro Diagnostics in Europe under MDR and IVDR
  • SAP S/4HANA Validation: A Streamlined Approach
  • Get Your Design in Control
  • Healthcare system resilience during and after the pandemic
  • Medical Device Risk Management for Patient and Product Safety
  • Bayesian Approaches for Incorporating Natural History Data in Studies of Rare and Pediatric Disease
  • Orphan Drugs for Rare Diseases in Children – Considerations for PIPs and PSPs
  • Basic rules of pharmaceutical advertising in France
  • Critical Regulatory Paths to Value Inflection
  • Post-Brexit 2021 Health and Life Science Sector Impact – Legal and Regulatory Overview
  • US NDA versus EU MAA eCTDs – Exploiting the Synergies and Mastering the Differences
  • Critical Considerations for Mergers & Acquisitions - legal and regulatory overview on due diligence
  • What you need to know to submit Study Data to FDA & what the new FDA Technical Rejection Criteria means for you
  • Central American Regulation for Drug Products (LATAM)
  • Unlocking BLA, NDA, IND Submissions Key considerations and LORENZ docuBridge training
  • Excipient Risk Assessment as per the EU Guidance and SMARTRISK as a solution
  • QbD – Analytical Quality by Design
  • Bayesian Adaptive Approaches in Rare and Pediatric Disease
  • Eudravigilance: overcoming challenges and gaining efficiencies with SMARTVIGISCREEN
  • Software Suite for the Life Cycle of Analytical Methods & Bioassays: Gain Trust in your Results
  • Brexit – Preparing for the end of the transition period and beyond
  • TGA (Australia) Approaches for Accelerated Medicine Approvals
  • Marketing a drug in France, what are the responsibilities of an exploitant?
  • Introduction to Bayesian Methodologies in CMC
  • QbD and Process Characterization
  • An Update to In Vitro Diagnostics Regulatory Requirements Worldwide
  • Biotech Drug Development Challenges and Case Studies (CMC)
  • Bayesian Power, Assurance and Probability of Success
  • Medical Device Software: Current Developments in the Regulatory World
  • Streamline Operations with Unified RIM system
  • Medical Device Clinical Evaluation Reports (CERs) -What you need to know
  • The applicability of EU Codes to pharma activities and materials
  • Virtual Audits Webinar
  • eCTD in China
  • Implementation of an efficient QRM program
  • Good Statistical Practices - Discovery to Clinical Research
  • Electronic Submission in the EAEU - the challenges
  • Marketing Cannabis in European Countries
  • Risk Management of the presence of Nitrosamines in medicines
  • Overview of the biotech drug development pathway
  • New legal requirements for electronic submissions in the EEU
  • Emerging Markets: LATAM
  • Early-Phase Modelling – Costs and Effectiveness in Pharma
  • EudraVigilance – The fundamental tool for Pharmacovigilance
  • Safety considerations for an Rx to OTC Switch Program
  • ClinPHLEX |Strategic & Cross-Functional Partnership
  • An Overview to Non clinical testing: why? when? what?
  • Vendor Management Programs - Ensuring Success!
  • Achieving and maintaining REG CMC Compliance
  • ISO IDMP Implementation in Europe
  • Environmental Risk Assessments for Human Medicinal Products
  • Brexit: An update on preparations for MA holders
  • Strategy For A Successful Quality By Design Implementation
  • Regulatory Landscape for Tissue, Cell and Gene Therapy
  • Mergers & Acquisitions related activities - A RA perspective
  • Manage your Temporary Authorization for Use (ATU) in France
  • Optimize your biosimilar development strategy
  • What you need to know to submit INDs in eCTD format
  • Learn how to get the most out of FDA meetings
  • A comprehensive approach to regulatory portfolio management

Infographics

  • INTEGRATED PRODUCT DEVELOPMENT - QUICK REFERENCE GUIDE
  • A guide to FDA meetings
  • Medical Device Regulations
  • Technical Helpdesk
  • Early Phase Modeling
  • Virtual Auditing for GxP Compliance
  • Biosimilar Development

Video & Animation

  • Using Bayesian Statistics for Clinical Research
  • Trends in and Solutions for Validation of Analytical Procedures and Bioassays
  • CSR at PharmaLex - Treedom
  • PharmaLex Commercial
  • PharmaLearn
  • PharmaLex at DIA Europe 2021 - Roundtable
  • Life Science Trends in 2021
  • SMARTRISK - Walkthrough the application
  • FORBES LEADER’S TALK: The challenges of the biotech market
  • Using Technology-enabled Smart Services - what are the benefits?
  • SMARTPHLEX - Technology-enabled Smart Solutions
  • SMARTRISK - What is SMARTRISK
  • Who are PharmaLex and what do we do?

CSR Documents

  • Supplier Code of Conduct
  • Pharmalex Code of Conduct

Related Services

  • About Us
  • ANDA Withdrawals
  • ATMP / Cell and Gene Therapy - Lorem ipsum dolor sit amet, consectetur adipiscing elit
  • Authorization / Approval
  • Biopharma
  • Biopharmaceuticals
  • Brexit
  • Careers
  • Choose A Service
  • Clinical Data Management
  • Clinical Development
  • Clinical Trial Applications
  • Clinical Trial Safety Support
  • CMC Services
  • Commercialization Readiness
  • Commissioning, Qualification, and Validation (CQV)
  • Computer System Validation (CSV)
  • Contact us
  • Corporate Social Responsibility
  • COVID-19 Authority Updates
  • COVID-19 Support
  • Custom Software Development
  • Customer On-site Support
  • Data Protection
  • Digital Health Teaser Tool
  • EU QPPV / National QPPV
  • Global End-to-End Outsourcing
  • Global Procedure Management
  • Global Reach
  • Global Statistics and Data Science
  • GxP Services
  • Health Authority / Agency Interaction
  • Healthcare Compliance and Medical Approval
  • Home
  • ICSR (Individual Safety Case Report) Management
  • Imprint
  • Industry Expertise
  • InfoDoc Login Test
  • Integrated Product Development
  • INTEGRATED PRODUCT DEVELOPMENT (IPD)
  • Interim / Contract QA
  • KNOWLEDGE ACCELERATED NEWSLETTER
  • Known Issue
  • Lab Tools
  • Literature Monitoring & Screening
  • MAA / NDA Submissions
  • Management Team
  • Market Access
  • Marketing and Labeling Activities
  • MedTech Services
  • Mergers and Acquisitions (M&A) Transfers
  • News & Events
  • Nitrosamines
  • Notifications
  • Our Milestones
  • PAI Readiness
  • Pharmacovigilance Consulting
  • Pharmacovigilance Quality & Compliance
  • Pharmacovigilance Systems
  • Post-approval / Maintenance
  • Post-Brexit Regulatory Support
  • Program Management
  • Q&A Showcase
  • Quality Management Systems
  • Regulatory Operations
  • Scientific Advice
  • Scientific, Regulatory and Technical Writing
  • Search
  • Signal Management
  • SMART MDR Teaser Tool
  • SMARTAUTOMATE
  • SMARTCHECK
  • SMARTCHECK MDR
  • SMARTCHECK-MDR
  • SMARTDECISIONS
  • SMARTENOVAL – analytical method validation software
  • SMARTPHLEX
  • SMARTPHLEX MDR & IVDR Assessment Contact Form
  • SMARTPHLEX MDR & IVDR Contact Form
  • SMARTRISK
  • SMARTSEELVA – bioassay validation software
  • SMARTSTABELITY – product stability and shelf-life estimation software
  • SMARTTRACE
  • SMARTTRANSVAL – analytical method transfer software
  • SMARTVIGICONTRACT
  • SMARTVIGILIT
  • SMARTVIGISCREEN
  • Statistical Services Contact Us
  • Statistical Training
  • Statistics and Data Sciences
  • Statistics Software Login
  • Tech Transfer / Scale-up
  • Technology Enabled Services
  • Terms and Conditions
  • The Discovery to Non-clinical Phase
  • Tobacco and Vape Products
  • Toxicology Services
  • TS XPT Generator
  • Virtual Audits
  • What Our Clients Say About Us
  • Working at PharmaLex
  • Your Application Process

What our clients say

Pharmalex provided the resources we needed to compile Investigational Medicinal Product Dossiers for our biological products. The dossiers were delivered on time with the trusted quality we expected

Small US Biopharmaceutical Company
Sr Director Regulatory Affairs CMC

Able to explain technical details so non-experts can understand

US based small / virtual company
Partner

Want to find out more?

PharmaLex. Confidence beyond compliance.

Contact us for more information
Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
4 May

Francesco Lanucara’s latest article discusses how important it is to provide clear information and keep up with regulatory guidelines.

Read the article here: https://lnkd.in/dFt4KBVy

For this and more articles subscribe to our newsletter.
#cellandgene #lifescience #cmc #ilap

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • We needed a partner to help us obtain device approval. PharmaLex have not only helped us achieve this but are now providing on-going post-marketing surveillance support. We would highly recommend them to anyone who needs specialist expertise.

    Med Device company, US
    Senior Regulatory Affairs Director
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.





    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for